CN107625771A - 一种miR‑17基因抑制剂及用于治疗胃癌的用途 - Google Patents
一种miR‑17基因抑制剂及用于治疗胃癌的用途 Download PDFInfo
- Publication number
- CN107625771A CN107625771A CN201710891241.3A CN201710891241A CN107625771A CN 107625771 A CN107625771 A CN 107625771A CN 201710891241 A CN201710891241 A CN 201710891241A CN 107625771 A CN107625771 A CN 107625771A
- Authority
- CN
- China
- Prior art keywords
- mir
- sulfamide derivative
- stomach cancer
- suppressing
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
磺酰胺衍生物A | 磺酰胺衍生物C | |
IC50值(μM) | 5.6 | 4.9 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710891241.3A CN107625771B (zh) | 2017-09-27 | 2017-09-27 | 一种miR-17基因抑制剂及用于治疗胃癌的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710891241.3A CN107625771B (zh) | 2017-09-27 | 2017-09-27 | 一种miR-17基因抑制剂及用于治疗胃癌的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107625771A true CN107625771A (zh) | 2018-01-26 |
CN107625771B CN107625771B (zh) | 2018-12-14 |
Family
ID=61102934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710891241.3A Active CN107625771B (zh) | 2017-09-27 | 2017-09-27 | 一种miR-17基因抑制剂及用于治疗胃癌的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107625771B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006060533A2 (en) * | 2004-12-01 | 2006-06-08 | Genentech, Inc. | Conjugates of 1, 8-bis-naphthalimides with an antibody |
WO2008007262A2 (en) * | 2006-06-19 | 2008-01-17 | Universidade Do Porto | Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity |
US20140057936A1 (en) * | 2012-08-27 | 2014-02-27 | University Of Tennessee Research Foundation | LPA2 Receptor-Specific Benzoic Acid Derivatives |
-
2017
- 2017-09-27 CN CN201710891241.3A patent/CN107625771B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006060533A2 (en) * | 2004-12-01 | 2006-06-08 | Genentech, Inc. | Conjugates of 1, 8-bis-naphthalimides with an antibody |
WO2008007262A2 (en) * | 2006-06-19 | 2008-01-17 | Universidade Do Porto | Bisnaphthalimidopropyl derivative compounds with anti-parasite and anti-cancer activity |
US20140057936A1 (en) * | 2012-08-27 | 2014-02-27 | University Of Tennessee Research Foundation | LPA2 Receptor-Specific Benzoic Acid Derivatives |
WO2014036038A1 (en) * | 2012-08-27 | 2014-03-06 | University Of Tennessee Research Foundation | Lpa2 receptor-specific benzoic acid derivatives |
Non-Patent Citations (1)
Title |
---|
RENUKADEVI PATIL,ET AL.: "Design and Synthesis of Sulfamoyl Benzoic Acid Analogues with Subnanomolar Agonist Activity Specific to the LPA2 Receptor", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
Also Published As
Publication number | Publication date |
---|---|
CN107625771B (zh) | 2018-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gu et al. | N6-methyladenosine mediates the cellular proliferation and apoptosis via microRNAs in arsenite-transformed cells | |
Fang et al. | Inhibition of GSK-3β activity suppresses HCC malignant phenotype by inhibiting glycolysis via activating AMPK/mTOR signaling | |
Matsubara et al. | Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92 | |
Bai et al. | Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line | |
Ramaiah et al. | miR-15/16 complex targets p70S6 kinase1 and controls cell proliferation in MDA-MB-231 breast cancer cells | |
Conti et al. | miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors | |
Liu et al. | Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction | |
Qin et al. | LSD1 sustains pancreatic cancer growth via maintaining HIF1α-dependent glycolytic process | |
Chang et al. | Passenger strand miRNA miR-31∗ regulates the phenotypes of oral cancer cells by targeting RhoA | |
Shu et al. | MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/protein kinase A pathway | |
Shen et al. | Feedback regulations of miR-21 and MAPKs via Pdcd4 and Spry1 are involved in arsenite-induced cell malignant transformation | |
Mukhopadhyay et al. | MicroRNA signatures of resveratrol in the ischemic heart | |
Mahmood et al. | PPAPDC1B and WHSC1L1 are common drivers of the 8p11-12 amplicon, not only in breast tumors but also in pancreatic adenocarcinomas and lung tumors | |
Ozer et al. | Oxidative stress and response to thymidylate synthase-targeted antimetabolites | |
Rizzo et al. | Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin | |
Zhao et al. | Long noncoding RNA H19 contributes to the proliferation and autophagy of glioma cells through mTOR/ULK1 pathway | |
Tu et al. | MicroRNAs mediated targeting on the Yin-yang dynamics of DNA methylation in disease and development | |
Seoane et al. | The mitochondrial genome is a “genetic sanctuary” during the oncogenic process | |
Chen et al. | Microrna-136 promotes proliferation and invasion ingastric cancer cells through Pten/Akt/P-Akt signaling pathway | |
Bricard et al. | The cytosolic 5′-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells | |
Zheng et al. | MicroRNA‑130a inhibits the proliferation, migration and invasive ability of hepatocellular carcinoma cells by downregulating Rho‑kinase 2 | |
Bai et al. | MiR-21 and let-7 cooperation in the regulation of lung cancer | |
Tian et al. | Aberrant MCM10 SUMOylation induces genomic instability mediated by a genetic variant associated with survival of esophageal squamous cell carcinoma | |
Hao et al. | Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development | |
CN107625771B (zh) | 一种miR-17基因抑制剂及用于治疗胃癌的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180614 Address after: 211505 D1 building, 9 Chuang Chuang Road, Zhongshan science and Technology Park, Liuhe District, Nanjing, Jiangsu. Applicant after: Nanjing qiannianjian stem cell gene engineering Co Ltd Address before: 810003 Chengbei Biological Park, Xining, Qinghai, No. 7, No. three road. Applicant before: Qinghai colorful flower Biotechnology Co., Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20181101 Address after: 221412 821, room 8, West 323 provincial road, industrial park, Xinyi, Xuzhou, Jiangsu Applicant after: Xuzhou Jiu Sheng Medical Instrument Co., Ltd. Address before: 211505 D1 building, 9 Chuang Chuang Road, Zhongshan science and Technology Park, Liuhe District, Nanjing, Jiangsu. Applicant before: Nanjing qiannianjian stem cell gene engineering Co Ltd |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |